Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, Runx1T1 in ovarian cancer

Epigenetics

Volumn 6, Issue 6, 2011, Pages 727-739

  Yeh, Kun Tu ^a,h,i   Chen, Tze Ho ^a   Yang, Hui Wen ^b   Chou, Jian Liang ^b   Chen, Lin Yu ^b   Yeh, Chia Ming ^b   Chen, Yu Hsin ^c   Lin, Ru Inn ^d   Su, Her Young ^b   Chen, Gary C W ^e   Deatherage, Daniel E ^e   Huang, Yi Wen ^e   Yan, Pearlly S ^e   Lin, Huey Jen ^e,f   Nephew, Kenneth P ^g   Huang, Tim H M ^e   Lai, Hung Cheng ^d   Chan, Michael W Y ^b  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

^c Buddist Tzu Chi General Hospital Dalin Branch   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e Immunology and Medical Genetics   (Taiwan)

^f OHIO STATE UNIVERSITY   (United States)

^g Indiana University School of Medicine   (United States)

^h KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

ⁱ CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Epigenetics; Ovarian cancer; RunX1T1; TGF

Indexed keywords

ATROGIN 1; HISTONE H3; SMAD4 PROTEIN; TRANSCRIPTION FACTOR RUNX1; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; COHORT ANALYSIS; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE SILENCING; GENETIC ASSOCIATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CELL CULTURE; PROMOTER REGION; SIGNAL TRANSDUCTION;

EID: 79958741371     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.6.6.15856     Document Type: Article

References (46)

1. Waite KA, Eng C. From developmental disorder to heritable cancer: it's all in the BMP/TGFβeta family. Nat Rev Genet 2003; 4:763-773.
2. Feng XH, Derynck R. Specificity and versatility in TGFβeta signaling through Smads. Annu Rev Cell Dev Biol 2005; 21:659-693.
3. Wong AS, Leung PC. Role of endocrine and growth factors on the ovarian surface epithelium. J Obstet Gynaecol Res 2007; 33:3-16.
4. Berchuck A, Rodriguez G, Olt G, Whitaker R, Boente MP, Arrick BA, et al. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines bytransforming growth factor-beta. Am J Obstet Gynecol 1992; 166:676-684.
5. Nilsson EE, Skinner MK. Role of transforming growth factor beta in ovarian surface epithelium biology and ovarian cancer. Reprod Biomed Online 2002; 5:254-258.
6. Yamada SD, Baldwin RL, Karlan BY. Ovarian carcinoma cell cultures are resistant to TGFβeta1-mediated growth inhibition despite expression of functional receptors. Gynecol Oncol 1999; 75:72-77.
7. Baldwin RL, Tran H, Karlan BY. Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factorbeta growth arrest independent of transforming growth factor beta/Smad signaling. Cancer Res 2003; 63:1413-1419.
8. Tanaka Y, Kobayashi H, Suzuki M, Kanayama N, Terao T. Transforming growth factor-beta1-dependent urokinase upregulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells. J Biol Chem 2004; 279:8567-8576.
9. Rodriguez GC, Haisley C, Hurteau J, Moser TL, Whitaker R, Bast RC Jr, et al. Regulation of invasion of epithelial ovarian cancer by transforming growth factorbeta. Gynecol Oncol 2001; 80:245-253.
10. Balch C, Fang F, Matei DE, Huang TH, Nephew KP. Minireview: epigenetic changes in ovarian cancer. Endocrinology 2009; 150:4003-4011.
11. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:415-428.
12. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-692.
13. Li B, Carey M, Workman JL. The role of chromatinduring transcription. Cell 2007; 128:707-719.
14. Chan MW, Huang YW, Hartman-Frey C, Kuo CT, Deatherage D, Qin H, et al. Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. Neoplasia 2008; 10:908-919.
15. Leu YW, Yan PS, Fan M, Jin VX, Liu JC, Curran EM, et al. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res 2004; 64:8184-8192.
16. Ren M, Pozzi S, Bistulfi G, Somenzi G, Rossetti S, Sacchi N. Impaired retinoic acid (RA) signal leads to RARbeta2 epigenetic silencing and RA resistance. Mol Cell Biol 2005; 25:10591-10603.
17. Qin H, Chan MW, Liyanarachchi S, Balch C, Potter D, Souriraj IJ, et al. An integrative ChIP-chip and gene expression profiling to model SMAD regulatory modules. BMC Syst Biol 2009; 3:73.
18. Chou JL, Su HY, Chen LY, Liao YP, Hartman-Frey C, Lai YH, et al. Promoter hypermethylation of FBXO32, a novel TGFβeta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest 2010; 90:414-425.
19. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93:9821-9826.
20. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68:4311-4320.
21. Davis JN, McGhee L, Meyers S. The ETO (MTG8) gene family. Gene 2003; 303:1-10.
22. Guo C, Hu Q, Yan C, Zhang J. Multivalent binding of the ETO corepressor to E proteins facilitates dual repression controls targeting chromatin and the basal transcription machinery. Mol Cell Biol 2009; 29:2644-2657.
23. Sunde JS, Donninger H, Wu K, Johnson ME, Pestell RG, Rose GS, et al. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res 2006; 66:8404-8412.
24. Evangelou A, Letarte M, Jurisica I, Sultan M, Murphy KJ, Rosen B, et al. Loss of coordinated androgen regulation in nonmalignant ovarian epithelial cells with BRCA1/2 mutations and ovarian cancer cells. Cancer Res 2003; 63:2416-2424.
25. Dumont N, Wilson MB, Crawford YG, Reynolds PA, Sigaroudinia M, Tlsty TD. Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci USA 2008; 105:14867-4872.
26. Chou JL, Chen LY, Lai HC, Chan MW. TGFβeta: friend or foe? The role of TGFβeta/SMAD signaling in epigenetic silencing of ovarian cancer and its implication in epigenetic therapy. Expert Opin Ther Targets 2010; 14:1213-1223.
27. Vikhanskaya F, Erba E, D'Incalci M, Broggini M. Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res 1994; 22:1012-1017.
28. Shin KS, Sullenger BA, Lee SW. Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA. Mol Ther 2004; 10:365-372.
29. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RC, Kelly KF, et al. P53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993; 53:2128-2132.
30. Okamoto A, Sameshima Y, Yokoyama S, Terashima Y, Sugimura T, Terada M, et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 1991; 51:5171-5176.
31. Tonks A, Pearn L, Musson M, Gilkes A, Mills KI, Burnett AK, et al. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia 2007; 21:2495-2505.
32. Liu S, Shen T, Huynh L, Klisovic MI, Rush LJ, Ford JL, et al. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res 2005; 65:1277-1284.
33. Watabe T, Miyazono K. Roles of TG Fbeta family signaling in stem cell renewal and differentiation. Cell Res 2009; 19:103-115.
34. Bierie B, Stover DG, Abel TW, Chytil A, Gorska AE, Aakre M, et al. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res 2008; 68:1809-1819.
35. Tang Y, Kitisin K, Jogunoori W, Li C, Deng CX, Mueller SC, et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGFβeta and IL-6 signaling. Proc Natl Acad Sci USA 2008; 105:2445-2450.
36. Tang B, Yoo N, Vu M, Mamura M, Nam JS, Ooshima A, et al. Transforming growth factorbeta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res 2007; 67:8643-8652.
37. Kulasingam V, Pavlou MP, Diamandis EP. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer 2010; 10:371-378.
38. Bertelsen K, Holund B, Andersen JE, Nielsen K, Stroyer I, Ladehoff P. Prognostic factors and adjuvant treatment in early epithelial ovarian cancer. Int J Gynecol Cancer 1993; 3:211-218.
39. Chan MW, Wei SH, Wen P, Wang Z, Matei DE, Liu JC, et al. Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res 2005; 11:7376-7383.
40. Wei SH, Balch C, Paik HH, Kim YS, Baldwin RL, Liyanarachchi S, et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 2006; 12:2788-2794.
41. Ahluwalia A, Yan P, Hurteau JA, Bigsby RM, Jung SH, Huang TH, et al. DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol Oncol 2001; 82:261-268.
42. Wei SH, Chen CM, Strathdee G, Harnsomburana J, Shyu CR, Rahmatpanah F, et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 2002; 8:2246-2252.
43. Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V) beta(5) integrins and promotes cell motility. Cancer Res 2002; 62:5358-5364.
44. Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T. BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics 2005; 21:4067-4068.
45. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 2003; 35:146-150.
46. Cheng AS, Jin VX, Fan M, Smith LT, Liyanarachchi S, Yan PS, et al. Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters. Mol Cell 2006; 21:393-404.